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Abstract: While the overall percentage of unused antiretroviral medicines returned to the 
hospital pharmacy is low, their cost is quite high. Adverse events, treatment failure, pharma-
cokinetic interactions, pregnancy, or treatment simplification are common reasons for unplanned 
treatment changes. Socially inefficient antiretroviral packages prevent the reuse of drugs returned 
to the hospital pharmacy. We defined antiretroviral package categories based on the excellence 
of drug packaging and analyzed the number of pills and costs of drugs returned during a period 
of 1 year in a hospital-based HIV unit attending to 2,413 treated individuals. A total of 6,090 
pills (34% of all returned antiretrovirals) – with a cost of 47,139.91€ – would be totally lost, 
mainly due to being packed up in the lowest efficiency packages. Newer treatments are packaged 
in low-excellence categories of packages, thus favoring the maintenance of these hidden costs 
in the near future. Therefore, costs of this low-efficiency drug packaging, where medication 
packages are started but not completed, in high-cost medications are substantial and should be 
properly addressed. Any improvement in the packaging by the manufacturer, and favoring the 
choice of drugs supplied through efficient packages (when efficacy, toxicity, and convenience 
are similar), should minimize the treatment expenditures paid by national health budgets.
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Introduction
Disbursement in antiretroviral treatment (ART) drugs within the context of a public 
health shortage of resources has increased the interest in pharmacoeconomical analyses 
of the available regimens for both treatment-naïve and -experienced individuals.1,2
In Western Europe, the classic concepts of efficacy, effectiveness, and 
efficiency – supported by the European Medicines Agency’s actions at the time of 
commercialization – must be completed with equity of care, the efficiency of drug 
packages, and their potential impact on public health budgets.3
In Spain, there is universal access to ART, and drugs are delivered by law only through 
hospital-based pharmacies. Not infrequently, patients return opened packages to the 
pharmacy due to unexpected toxicity, treatment changes, pharmacokinetic interactions, 
pregnancy, or incomplete adherence.4 The efficiency of these packages, which vary sig-
nificantly in their quality standards, has an influence on their potential for reuse, and the 
impact on the cost of treatment for the health system may eventually be considerable.5
Socially efficient packaging in ambulatory care hospital-dispensed drugs should be 
the one that is best adapted to unit-dose dispensation. In addition, it should facilitate 
patient compliance, allowing for an easy and hygienic review of the ingested and 
remaining doses with no need to manipulate either the packaging or the pharmaceuti-
cal forms, particularly those that are unused. Moreover, in directly observed ART, 
drugs that are properly packed permit better control, allowing the delivery of just the 
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needed doses in every dispensation (ie, adjusted to weekly 
methadone delivery in drug users).
We established antiretroviral package categories based on 
the excellence of drug packaging and analyzed the number of 
pills and the cost of drugs returned during a period of 1 year 
in a hospital-based HIV unit.
Methods
We defined a classification system for the so-called social 
efficiency of antiretroviral drug packages that could also be 
applicable to any other family of high-cost drugs used for 
outpatients or inpatients (ie, hepatitis C direct antivirals). 
The classes were as follows:
Class A: Drug packed in unit doses with complete information 
(name of the drug, dosage in mg, lot number, and expiry 
date) in each unit, thus maintaining complete information 
if returned when the external package is opened. No unit 
doses are opened in the returned packages (Figure 1).
Class B: Drug packed in blisters with complete information 
only in the blister, but not in every unit dose, without 
special conservation conditions. Should be initially 
repackaged in unit doses in the pharmacy before dispensa-
tion to ensure class A excellence, with complete tracking 
information in every unit.
Class C: Drug packed in plastic containers with complete 
information written only on a label over the container, 
with no special conservation conditions. It would allow 
to supply a repackaged drug to the patient.
Class D: Drug packed in plastic containers with any manufac-
turer’s warning that the product cannot be placed outside of 
the original package due to special conditions of conserva-
tion (fridge, humidity) that will not allow either initial unit 
dose repackaging or reusing an opened container.
Class B and class C packing increase pharmacy department 
budgets in terms of human resources, time, and repacking 
materials. In class D packing, all of the contents will be lost 
once the container is opened, regardless of being returned.
In order to deliver only the necessary amount of pills until 
the next visit, or to deliver a predefined schedule of medica-
tion via each pharmacy department, class A packages would 
exhibit optimal social efficiency, whereas class D would 
demonstrate the worst. Depending on the social efficiency 
of the drug that patients withdraw, the returned “old” one 
would immediately become a wasted drug.
The change of a class B or class C drug into a class A 
drug requires internal pharmacy technician work. The current 
cost of this change is approximately 0.034€ per pill, accord-
ing to conditioning material suppliers and human resources 
obtained through our hospital price list. An experienced 
technician repackages approximately 214 pills per hour 
(1,500 pills/day).
Results
The hospital-based pharmacy in our HIV unit served 2,413 
treated individuals during the year of study. Patients gener-
ated 23,574 visits to the pharmacy during this period, and they 
experienced a total of 1,051 treatment changes for any reason. 
Most of the treatment changes were not foreseeable.
The pharmacy department delivered 48,325 antiretro-
viral drug packages (2,529,137 pills). A total amount of 
122,945€ was returned in opened antiretroviral packages. 
Of these packages, 6,090 pills (34% of all returned antiret-
rovirals) – with a cost of 47,139.91€ – would be totally lost, 
mainly due to being packed up in class C and class D boxes. 
This would be the equivalent to treating 78 individuals with a 
standard coformulation of rilpivirine/tenofovir/emtricitabine 
during 1 month.
We have classified all the current ART specialties 
depending on their social efficiency as supplied in Spain, 
the UK, and the USA (Table 1). US packaging shows a 
Figure 1 Class A and D packaging.
Notes: (A) Class A (optimal social efficiency) packaging of a drug featuring unit doses with complete information (name of the drug, dosage in mg, lot number, and expiry 
date) in each unit. (B) Class D (lowest social efficiency) packaging in plastic containers with the manufacturer’s warning that the product cannot be placed outside of the 
original package due to special conditions of conservation (humidity).
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greater deal of class C and class D bottles when compared 
to Europe.
Class A and class B packages returned in bad condition 
represented only 1.1% of the cost and 75,805€ came from 
returned packages in good condition that could potentially 
be reused.
Discussion
During a period of 1 year, the percentage of antiretroviral 
drugs returned to the hospital pharmacy was low. However, 
the cost of these drugs is high, and therefore there is a 
significant economic budget loss through unused antiretro-
viral medicines returned to the hospital pharmacy that cannot 
be reused due to being supplied in low-excellence packages 
(approximately one-third of all returned packages).
For hospital inpatients, the excellence in use of ART 
requires class A packed drugs that allow for administration 
in unit doses, thus minimizing time hours consumed by 
nurses in drug administration, reducing medication errors, 
and improving drug stocks in hospital wards.
The European Commission has singled out specific coun-
tries to make particular recommendations to increase the cost 
effectiveness of the health care sector, and in the case of Spain, 
there is particular interest in further rationalizing pharmaceutical 
spending, including ambulatory drugs dispensed in hospitals.6 
Further to this point, the European Association of Hospital 
Pharmacists has encouraged European authorities to identify 
the drug with all the items we define as class A efficiency, and 
also to include a barcode to allow unit dose administration in 
hospitals. Barcode technology substantially reduces the rate 
Table 1 Efficiency class of all antiretroviral drugs available in Spain, the USA, and the UK
Drug Efficiency class of the packaging License  
year, Spain Spain US UK
retrovir® 100 mg, 250 mg, or 300 mg A C A 1987
reyataz® 200 mg A C C 2004
Sustiva® 600 mg A C A 2002
Viramune® 200 mg or 400 xr mg A A A 2011
Zidovudine® 100 mg, 250 mg, or 300 mg** A n/A n/A 1996
Teva-Efavirenz® 600 mg** A n/A n/A 2013
nevirapine Teva® 200 mg** A n/A n/A 2012
Celsentri® 150 mg or 300 mg B C B 2007
Kaletra® tablets B D B 2010
Kivexa® 600–300/Epzicom® 1 pill once-a-day B C B 2004
Trizivir® capsules B C B 2001
Videx® 200 mg, 250 mg, or 400 mg B D* B 2000
Zerit® 20 mg, 30 mg, or 40 mg B D* B 1996
Ziagen® 300 mg B B B 1999
Lamivudine generic 300 mg (normon®)** B n/A n/A 2012
Combivir® one pill twice daily B B, C B 1998
Emtriva® 200 mg C C D 2003
Epivir® 150 mg or 300 mg C C C 2002
invirase® 500 mg C D* n/A 2005
isentress® C C C 2007
prezista® 600 mg or 800 mg C C C 2009
reyataz® 200 mg or 300 mg C C C 2008
Sustiva® 200 mg C C C 1999
Telzir® 700 mg/Lexiva® one pill twice daily C D* C 2004
Tivicay® C C C 2014
Viread® 245 mg C D* C 2002
Aptivus® 250 mg D D D 2005
Atripla® D D D 2007
Crixivan® 200 mg or 400 mg D D D 1996
Edurant® D D D 2012
Eviplera/Complera® D D D 2012
intelence® 100 mg and 200 mg D D D 2008, 2011
norvir® 100 mg tablets D D D 2010
Stribild® D D D 2013
Truvada® 200–245 mg one pill once-a-day D D D 2005
Triumeq® one pill once daily D D D 2015
Notes: *“Keep container tightly closed” is specified by the manufacturer in the container. **Generic drugs analyzed only in Spain brands.
Abbreviation: n/A, not applicable.
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of errors in order transcription and medication administration, 
and it reduces potential adverse drug events and interactions.7
Establishing strategies to reduce the waste of unused 
medicines is an unmet need.4,5,8 Unopened unit dose (class A) 
drugs that are returned inside the hospitals can be reused. 
However, in ambulatory care, this reusing is usually not 
allowed due to the impossibility of granting the quality of 
drugs once delivered to outpatients.
Unfortunately, newer antiretrovirals – mainly, the new three 
drug combos, Eviplera/Complera, Stribild, and Triumeq,– are 
commonly packaged in class C and class D categories, thus 
promoting the maintenance of these hidden costs in the near 
future. Any improvement in the excellence of packaging by 
the manufacturer, and favoring the choice of drugs supplied 
through more efficient packages (whenever efficacy, toxic-
ity, and convenience are similar), should minimize treatment 
expenditures paid by national health budgets.
Conclusion
In summary, while the overall percentage of unused anti-
retroviral medicines returned to the hospital pharmacy is 
low, their cost is quite high. Therefore, the hidden costs of 
this low-efficiency drug packaging in wasted drugs in these 
kinds of medications are substantial and should be properly 
addressed.
Drug regulatory authorities should consider including the 
concept of social efficiency of the packaging in the autho-
rization process of high-cost specialty medicines delivered 
through hospital dispensing to ambulatory patients, as many 
of these drugs are actually manufactured in Europe.
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